bioRxiv ScienceSearch

Biology subjects

Pergola, G.

Publications and source records attributed to Pergola, G..

5 recordsLinked to original sources

Genetic control of variability in subcortical and intracranial volumes

Sensitivity to external demands is essential for adaptation to dynamic environments, but comes at the cost of increased risk of adverse outcomes when facing poor environmental conditions. Here, we apply a novel methodology to perform genome-wide association analysis of mean and variance in nine key brain features (accumbens, amygdala, caudate, hippocampus, pallidum, putamen, thalamus, intracranial volume and cortical thickness), integrating genetic and neuroanatomical data from a large lifespan sample (n=25,575 individuals; 8 to 89 years, mean age 51.9 years). We identify genetic loci associated with phenotypic variability in cortical thickness, thalamus, pallidum, and intracranial volumes. The variance-controlling loci included genes with a documented role in brain and mental health and were not associated with the mean anatomical volumes. This proof-of-principle of the hypothesis of a genetic regulation of brain volume variability contributes to establishing the genetic basis of phenotypic variance (i.e., heritability), allows identifying different degrees of brain robustness across individuals, and opens new research avenues in the search for mechanisms controlling brain and mental health.

neuroscience

The dark side of the mean: brain structural heterogeneity in schizophrenia and its polygenic risk.

ImportanceBetween-subject variability in brain structure is determined by gene-environment interactions, possibly reflecting differential sensitivity to environmental and genetic perturbations. Magnetic resonance imaging (MRI) studies have revealed thinner cortices and smaller subcortical volumes in patients. However, such group-level comparisons may mask considerable within-group heterogeneity, which has largely remained unnoticed in the literature\n\nObjectiveTo compare brain structural variability between individuals with SZ and healthy controls (HC) and to test if respective variability reflects the polygenic risk for SZ (PRS) in HC.\n\nDesign, Setting, and ParticipantsWe compared MRI derived cortical thickness and subcortical volumes between 2,010 healthy controls and 1,151 patients with SZ across 16 cohorts. Secondly, we tested for associations between PRS and MRI features in 12,490 participants from UK Biobank.\n\nMain Outcomes and MeasuresWe modeled mean and dispersion effects of SZ and PRS using double generalized linear models. We performed vertex-wise analyses for thickness, and region-of-interest analysis for cortical, subcortical and hippocampal subfield volumes. Follow-up analyses included within-sample analysis, controlling for intracranial volume and population covariates, test of robustness of PRS threshold, and outlier removal.\n\nResultsCompared to controls, patients with SZ showed higher heterogeneity in cortical thickness, cortical and ventricle volumes, and hippocampal subfields. Higher PRS was associated with thinner frontal and temporal cortices, as well as smaller left CA2/3, but was not significantly associated with dispersion.\n\nConclusion and relevanceSZ is associated with substantial brain structural heterogeneity beyond the mean differences. These findings possibly reflect higher differential sensitivity to environmental and genetic perturbations in patients, supporting the heterogeneous nature of SZ. Higher PRS for SZ was associated with thinner fronto-temporal cortices and smaller subcortical volumes, but there were no significant associations with the heterogeneity in these measures, i.e. the variability among individuals with high PRS were comparable to the variability among individuals with low PRS. This suggests that brain variability in SZ results from interactions between environmental and genetic factors that are not captured by the PGR. Factors contributing to heterogeneity in fronto-temporal cortices and hippocampus are thus key to further our understanding of how genetic and environmental factors shape brain biology in SZ.\n\nKey PointsQuestion: Is schizophrenia and its polygenic risk associated with brain structural heterogeneity in addition to mean changes?\n\nFindings: In a sample of 1151 patients and 2010 controls, schizophrenia was associated with increased heterogeneity in fronto-temporal thickness, cortical, ventricle, and hippocampal volumes, besides robust reductions in mean estimates. In an independent sample of 12,490 controls, polygenic risk for schizophrenia was associated with thinner fronto-temporal cortices and smaller CA2/3 of the left hippocampus, but not with heterogeneity.\n\nMeaning: Schizophrenia is associated with increased inter-individual differences in brainstructure, possibly reflecting clinical heterogeneity, gene-environment interactions, or secondary disease factors.

neuroscience

Increased Cerebral Blood Flow after single dose of antipsychotics in healthy volunteers depends on dopamine D2 receptor density profiles.

As a result of neuro-vascular coupling, the functional effects of antipsychotics in human brain have been investigated in both healthy and clinical populations using haemodynamic markers such as regional Cerebral Blood Flow (rCBF). However, the relationship between observed haemodynamic effects and the pharmacological action of these drugs has not been fully established. Here, we analysed MRI-based rCBF data from a placebo-controlled study in healthy volunteers, who received a single dose of three different D2 receptor antagonists and tested the association of the main effects of the drugs on rCBF against normative population maps of D2R protein density and gene-expression data. In particular, we correlated CBF changes after antipsychotic administration with non-displaceable binding potential (BPND) template maps of the high affinity D2-antagonist Positron Emission Tomography (PET) ligand [18F]Fallypride and brain post-mortem microarray mRNA expression data for the DRD2 gene. For all antipsychotics, rCBF changes were directly proportional to brain D2R densities and DRD2 mRNA expression measures, although PET BPND spatial profiles explained more variance as compared with mRNA profiles (PET R2 range= 0.20-0.60, mRNA PET R2 range 0.04-0.20, pairwise-comparisons all p<0.05). In addition, the spatial coupling between {Delta}CBF and D2R profiles varied between the different antipsychotics tested, possibly reflecting differential affinities. Overall, these results indicate that the functional effects of antipsychotics as measured with rCBF are tightly correlated with the distribution of their target receptors in striatal and extra-striatal regions. Our results further demonstrate the link between neurotransmitter targets and haemodynamic changes reinforcing rCBF as a robust in-vivo marker of drug effects. This work is important in bridging the gap between pharmacokinetic and pharmacodynamics of novel and existing compounds.

pharmacology and toxicology

Prefrontal co-expression of schizophrenia risk genes is associated with treatment response in patients

Gene co-expression networks are relevant to functional and clinical translation of schizophrenia (SCZ) risk genes. We hypothesized that SCZ risk genes may converge into coexpression pathways which may be associated with gene regulation mechanisms and with response to treatment in patients with SCZ. We identified gene co-expression networks in two prefrontal cortex post-mortem RNA sequencing datasets (total N=688) and replicated them in four more datasets (total N=227). We identified and replicated (all p-values<.001) a single module enriched for SCZ risk loci (13 risk genes in 10 loci). In silico screening of potential regulators of the SCZ risk module via bioinformatic analyses identified two transcription factors and three miRNAs associated with the risk module. To translate post-mortem information into clinical phenotypes, we identified polymorphisms predicting co-expression and combined them to obtain an index approximating module co-expression (Polygenic Co-expression Index: PCI). The PCI-co-expression association was successfully replicated in two independent brain transcriptome datasets (total N=131; all p-values<.05). Finally, we tested the association between the PCI and short-term treatment response in two independent samples of patients with SCZ treated with olanzapine (total N=167). The PCI was associated with treatment response in the positive symptom domain in both clinical cohorts (all p-values<.05).\n\nIn summary, our findings in a large sample of human post-mortem prefrontal cortex show that coexpression of a set of genes enriched for schizophrenia risk genes is relevant to treatment response. This co-expression pathway may be co-regulated by transcription factors and miRNA associated with it.

neuroscience

Brain scans from 21297 individuals reveal the genetic architecture of hippocampal subfield volumes

The hippocampus is a heterogeneous structure, comprising histologically distinguishable subfields. These subfields are differentially involved in memory consolidation, spatial navigation and pattern separation, complex functions often impaired in individuals with brain disorders characterized by reduced hippocampal volume, including Alzheimers disease (AD) and schizophrenia. Given the structural and functional heterogeneity of the hippocampal formation, we sought to characterize the subfields genetic architecture. T1-weighted brain scans (n=21297, 16 cohorts) were processed with the hippocampal subfields algorithm in FreeSurfer v6.0. We ran a genome-wide association analysis on each subfield, covarying for total hippocampal volume. We further calculated the single nucleotide polymorphism (SNP)-based heritability of twelve subfields, as well as their genetic correlation with each other, with other structural brain features, and with AD and schizophrenia. All outcome measures were corrected for age, sex, and intracranial volume. We found 15 unique genome-wide significant loci across six subfields, of which eight had not been previously linked to the hippocampus. Top SNPs were mapped to genes associated with neuronal differentiation, locomotor behaviour, schizophrenia and AD. The volumes of all the subfields were estimated to be heritable (h2 from .14 to .27, all p< 1x10-16) and clustered together based on their genetic correlations compared to other structural brain features. There was also evidence of genetic overlap of subicular subfield volumes with schizophrenia. We conclude that hippocampal subfields have partly distinct genetic determinants associated with specific biological processes and traits. Taking into account this specificity may increase our understanding of hippocampal neurobiology and associated pathologies.

genetics